# A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia

> **NCT02714569** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 60 (actual)

## Conditions studied

- Dyslipidemias

## Interventions

- **DRUG:** LY3202328
- **DRUG:** Placebo
- **DRUG:** Atorvastatin
- **DRUG:** Simvastatin

## Key facts

- **NCT ID:** NCT02714569
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2017-02-15
- **Final completion:** 2017-02-15
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2021-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02714569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02714569, "A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02714569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*